M&A / Deals AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B BioSpaceDizal Pharmaceutical's Zegfrovy is approved in the U.S.OncologyRead full story pharminent July 14, 2026 (Last updated: July 15, 2026) BioSpace Dizal Pharmaceutical’s Zegfrovy is approved in the U.S. Oncology Read full story Post navigation Previous: Novartis and Chai Discovery collaborate on antibody identificationNext: Spero snaps up Innovent immunology drug in strategic pivot Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026